Hikma Eyes Return To Growth After Further Cutting Generics Forecasts
Injectables And Branded Increases Offset 18% Sales Slide For Generics Unit In First Half
Executive Summary
Hikma has once again downgraded its expectations for its generics business in 2022 as it revealed a first-half drop of 18% in sales for the unit. However, injectables and branded increases helped to offset the decline, while the company maintained that generics growth was on the horizon in 2023.
You may also be interested in...
Who’s Hired? Former Hikma Chief Olafsson Takes Lead At Mallinckrodt
Siggi Olafsson has taken the reins at Mallinckrodt after stepping down as Hikma’s CEO. At the same time, Teva has named a new global R&D and chief medical officer while Piramal Pharma Solutions has appointed a fresh COO and Formycon has added to its supervisory board.
Hikma Explores Fresh Opportunity In France
Hikma has expanded its European presence by establishing a subsidiary in France, marking its “official entry” into the major market following previous supplies through a third-party partner.
Hikma Searches For New CEO As Olafsson Resigns
Hikma is looking for a new CEO after announcing that chief executive Siggi Olafsson will be leaving the company “to pursue other opportunities” on 24 June. In the meantime, executive chairman and former CEO Said Darwazah will take on his leadership responsibilities.